Core Insights - Innovent Biologics has successfully closed a global strategic collaboration with Takeda, aimed at accelerating the development and commercialization of next-generation immuno-oncology and antibody-drug conjugate therapies [1][2][3] Financial Details - Takeda will make an upfront payment of US$1.2 billion, which includes a US$100 million equity investment in Innovent at a premium price of HK$112.56 per share [3] - The total deal value could reach up to US$11.4 billion, including potential milestone payments of approximately US$10.2 billion for the development and sales of IBI363, IBI343, and IBI3001 [3] Collaboration Structure - Innovent and Takeda will co-develop IBI363 globally and co-commercialize it in the U.S., with Takeda leading these efforts [7] - Takeda has been granted exclusive commercialization rights for IBI363 outside Greater China and the U.S., along with global manufacturing rights for IBI363 outside Greater China [7] - Takeda also holds exclusive global rights to develop, manufacture, and commercialize IBI343 outside Greater China, and has an option to license global rights for IBI3001 [7] Company Background - Innovent Biologics is a leading biopharmaceutical company founded in 2011, focusing on affordable, high-quality biopharmaceuticals targeting various diseases [5] - The company has launched 17 products and has multiple assets in various stages of clinical trials, partnering with over 30 global healthcare companies [5]

智通财经APP讯，信达生物(01801)发布公告，内容有关信达生物与武田制药(透过武田制药全资附属公 司Takeda Pharmaceuticals International AG)达成全球战略合作，许可、选择权及合作协议及股份发行协 议各自的所有先决条件均已达成或获豁免(如适用)。因此，许可、选择权及合作协议已完成及股份发行 协议于2025年12月4日完成。 于股份发行协议完成后，公司向认购人配发及发行691.38万股股份，占发行认购股份后公司已发行股本 的约0.40%。配发及发行认购股份的所得款项总额约为7.78亿港元(按每股认购股份112.56港元的认购价 计算)，而所得款项净额约为7.77亿港元。 ...

信达生物(01801)发布公告，内容有关信达生物与武田制药(透过武田制药全资附属公司Takeda Pharmaceuticals International AG)达成全球战略合作，许可、选择权及合作协议及股份发行协议各自的所 有先决条件均已达成或获豁免(如适用)。因此，许可、选择权及合作协议已完成及股份发行协议于2025 年12月4日完成。 于股份发行协议完成后，公司向认购人配发及发行691.38万股股份，占发行认购股份后公司已发行股本 的约0.40%。配发及发行认购股份的所得款项总额约为7.78亿港元(按每股认购股份112.56港元的认购价 计算)，而所得款项净额约为7.77亿港元。 ...

于股份发行协议完成后，公司向认购人配发及发行691.38万股股份，占发行认购股份后公司已发行股本 的约0.40%。配发及发行认购股份的所得款项总额约为7.78亿港元(按每股认购股份112.56港元的认购价 计算)，而所得款项净额约为7.77亿港元。 格隆汇12月5日丨信达生物(01801.HK)宣布，许可、选择权及合作协议及股份发行协议各自的所有先决 条件均已达成或获豁免(如适用)。因此，许可、选择权及合作协议已完成及股份发行协议于2025年12月 4日完成。 ...

FF305 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 01801 | 說明 | 普通股每股面值0.00001美元 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | | 庫存股份數目 | 每股發行/出售價 (註4) | | 已發行股 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考之用，並不構成收購、購買或認購本公司任何證券之邀請或要約。 信達生物製藥 INNOVENT BIOLOGICS, INC. （於開曼群島註冊成立的有限公司） （股份代號：1801） 完成與武田製藥的全球戰略合作及根據一般授權發行股份 董事會欣然宣佈，許可、選擇權及合作協議及股份發行協議各自之所有先決條件 均已達成或獲豁免（如適用）。因此，許可、選擇權及合作協議已完成及股份發行 協議於2025年12月4日完成。 於股份發行協議完成後，本公司向認購人配發及發行6,913,834股股份，佔發行認 購股份後本公司已發行股本之約0.40%。配發及發行認購股份之所得款項總額約 為778百萬港元（按每股認購股份112.56港元之認購價計算），而所得款項淨額（經 扣除配發及發行認購股份之所有相關開支後）約為777百萬港元。有關所得款項用 途之進一步詳情，請參閱該公告。 認購股份乃根據一般授權發行。一般授權 ...

Core Viewpoint - The Hong Kong stock market's innovative drug concept stocks are experiencing a continuous rebound, with notable increases in share prices for several companies [1] Group 1: Company Performance - Gilead Sciences-B has seen a rise of over 9% [1] - WuXi Biologics has increased by more than 6% [1] - Other companies such as Rongchang Biopharmaceutical, Innovent Biologics, and I-Mab have also shown upward movement in their stock prices [1]

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (00728) at 72.68%, Green Power Environmental (01330) at 69.12%, and Da Zhong Public Utilities (01635) at 69.03% [1] - Alibaba-W (09988), Meituan-W (03690), and Pop Mart (09992) saw the largest increases in holding amounts over the last five trading days, with increases of +3.329 billion, +1.319 billion, and +1.060 billion respectively [1] - The largest decreases in holding amounts were observed in Zijin Mining (02899) at -861 million, SMIC (00981) at -815 million, and Lenovo Group (00992) at -430 million [1][2] Hong Kong Stock Connect Holding Ratios - China Telecom (00728): 100.87 billion shares, 72.68% holding ratio [1] - Green Power Environmental (01330): 2.80 billion shares, 69.12% holding ratio [1] - Da Zhong Public Utilities (01635): 3.68 billion shares, 69.03% holding ratio [1] - Other notable companies include Haotian International Construction Investment (01341) at 68.75% and China Shenhua (01088) at 67.00% [1] Recent Increases in Holdings (Last 5 Trading Days) - Alibaba-W (09988): +3.329 billion, +21.6752 million shares [1] - Meituan-W (03690): +1.319 billion, +13.7526 million shares [1] - Pop Mart (09992): +1.060 billion, +4.9058 million shares [1] - Other companies with significant increases include ZTE Corporation (00763) and China Merchants Bank (03968) [2] Recent Decreases in Holdings (Last 5 Trading Days) - Zijin Mining (02899): -861 million, -26.2640 million shares [2] - SMIC (00981): -815 million, -12.1252 million shares [2] - Lenovo Group (00992): -430 million, -43.6821 million shares [2] - Other companies with notable decreases include China Mobile (00941) and China Pacific Insurance (02328) [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01801 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,713,783,235 | | 0 | | 1,713,783,235 | | 增加 / 減少 (-) | | | 80,001 | | 0 | | | | 本月底結存 | | | 1,713,863,236 | | 0 | | 1,713,863,236 | 公司名稱: 信達生物製藥 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | ...

Core Viewpoint - The Hong Kong stock market is experiencing a pullback, but there is a counter-trend inflow of funds, particularly into the Hong Kong Technology ETF (159751), which saw a net subscription of 10 million units. The market is expected to continue its upward trend due to strong overall profitability and the scarcity of assets in sectors like the internet, new consumption, and innovative pharmaceuticals, alongside the anticipated interest rate cut by the Federal Reserve in December [1]. Group 1 - The Hong Kong Technology ETF (159751) closely tracks the CSI Hong Kong Stock Connect Technology Index, which selects 50 large-cap, high R&D investment, and high revenue growth technology companies to reflect the overall performance of technology leaders in the Hong Kong Stock Connect [1]. - As of December 3, 2025, the CSI Hong Kong Stock Connect Technology Index (931573) shows mixed performance among its constituent stocks, with Huahong Semiconductor (01347) leading with a 2.40% increase, followed by Gao Wei Electronics (01415) at 1.81%, and BYD Electronics (00285) at 1.28% [1]. - The overall valuation of the Hong Kong stock market remains low despite several months of increases, indicating a high long-term allocation cost-performance ratio [1]. Group 2 - As of November 28, 2025, the top ten weighted stocks in the CSI Hong Kong Stock Connect Technology Index (931573) include Alibaba-W (09988), Tencent Holdings (00700), and SMIC (00981), with these ten stocks accounting for 67.26% of the index [2].